We review our first research notes of 2026 and summarise investor sentiment on large pharma after our annual January 50@50 (speedy zooms). We have termed 2026 “The Battle of the Pills”. Great news for patients – not just in obesity but also breast cancer, lung cancer, multiple sclerosis, cardiomyopathy, hypertension, cholesterolaemia, atopic dermatitis & beyond.